Dec 08, 2022 6:30am EST Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
Dec 02, 2022 7:30am EST Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
Nov 11, 2022 9:00am EST Immunocore presents new biomarker analysis for KIMMTRAK (tebentafusp-tebn) in metastatic uveal melanoma at the SITC 2022 Annual Meeting
Nov 09, 2022 7:00am EST Immunocore Reports Third Quarter 2022 Financial Results and Provides Business Update
Sep 09, 2022 10:00am EDT Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
Aug 10, 2022 7:00am EDT Immunocore Reports Second Quarter 2022 Financial Results and Provides Business Update
Aug 03, 2022 7:00am EDT Immunocore to Report Second Quarter 2022 Earnings and Host Call on August 10, 2022
Aug 01, 2022 7:00am EDT Immunocore announces upcoming oral presentation of initial Phase 1 data of ImmTAC® candidate IMC-F106C targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022